OTCMKTS:BSTG - Biostage Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.80 0.00 (0.00 %) (As of 05/24/2019 06:55 AM ET)Previous Close$2.80Today's Range$2.80 - $2.8052-Week Range$0.75 - $5.85Volume3,023 shsAverage Volume3,260 shsMarket Capitalization$18.68 millionP/E RatioN/ADividend YieldN/ABeta2.44 ProfileChartEarningsFinancialsInsider TradesHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan organ implants. It is developing bioengineered organ implants, which addresses the damage of the esophagus, bronchus, and trachea due to cancer, infection, trauma, or congenital abnormalities. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts. Receive BSTG News and Ratings via Email Sign-up to receive the latest news and ratings for BSTG and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:BSTG Previous Symbol CUSIPN/A CIK1563665 Webhttp://www.biostage.com/ Phone774-233-7300Debt Debt-to-Equity Ratio0.03 Current Ratio1.81 Quick Ratio1.81Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$80,000.00 Price / Sales233.52 Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book14.00Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-7,530,000.00 Net MarginsN/A Return on Equity-258.99% Return on Assets-195.45%Miscellaneous Employees15 Outstanding Shares6,672,000Market Cap$18.68 million Next Earnings Date8/13/2019 (Estimated) OptionableNot Optionable Biostage (OTCMKTS:BSTG) Frequently Asked Questions What is Biostage's stock symbol? Biostage trades on the OTCMKTS under the ticker symbol "BSTG." How were Biostage's earnings last quarter? Biostage Inc (OTCMKTS:BSTG) posted its quarterly earnings data on Tuesday, May, 14th. The company reported ($0.32) EPS for the quarter. View Biostage's Earnings History. When is Biostage's next earnings date? Biostage is scheduled to release their next quarterly earnings announcement on Tuesday, August 13th 2019. View Earnings Estimates for Biostage. Has Biostage been receiving favorable news coverage? Media coverage about BSTG stock has been trending negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Biostage earned a media sentiment score of -2.7 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the next several days. Who are some of Biostage's key competitors? Some companies that are related to Biostage include Motus GI (MOTS), CAS Medical Systems (CASM), STRATA Skin Sciences (SSKN), Repro-Med Systems (REPR), RA Medical Systems (RMED), Titan Medical (TMDI), Invo Bioscience (IVOB), Pro-Dex (PDEX), Spectral Medical (EDTXF), AIT Therapeutics (AITB), Arch Therapeutics (ARTH), Nephros (NEPH), Alliqua Biomedical (ALQA), Neovasc (NVCN) and PAVmed (PAVM). What other stocks do shareholders of Biostage own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biostage investors own include Allena Pharmaceuticals (ALNA), Wheeler Real Estate Investment Trust (WHLR), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), AcelRx Pharmaceuticals (ACRX), Advanced Emissions Solutions (ADES), Aldeyra Therapeutics (ALDX), Apellis Pharmaceuticals (APLS), Aquinox Pharmaceuticals (AQXP) and Ardelyx (ARDX). Who are Biostage's key executives? Biostage's management team includes the folowing people: Mr. James J. McGorry, CEO & Director (Age 63)Mr. Thomas W. McNaughton, CFO & Sec. (Age 59)Yu Hong, Pres (Age 46)Ms. Ginger A. Abraham-Freel, Director of Quality & OperationsDr. William L. Fodor Ph.D., Chief Scientific Officer (Age 60) How do I buy shares of Biostage? Shares of BSTG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Biostage's stock price today? One share of BSTG stock can currently be purchased for approximately $2.80. How big of a company is Biostage? Biostage has a market capitalization of $18.68 million and generates $80,000.00 in revenue each year. Biostage employs 15 workers across the globe. What is Biostage's official website? The official website for Biostage is http://www.biostage.com/. How can I contact Biostage? Biostage's mailing address is 84 October Hill Road Suite 11, Holliston MA, 01746. The company can be reached via phone at 774-233-7300 or via email at [email protected] MarketBeat Community Rating for Biostage (OTCMKTS BSTG)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 26 (Vote Outperform)Underperform Votes: 15 (Vote Underperform)Total Votes: 41MarketBeat's community ratings are surveys of what our community members think about Biostage and other stocks. Vote "Outperform" if you believe BSTG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BSTG will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/24/2019 by MarketBeat.com StaffFeatured Article: Earnings Per Share (EPS) Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.